Steven D. Nathan

23.9k total citations · 6 hit papers
319 papers, 14.3k citations indexed

About

Steven D. Nathan is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Physiology. According to data from OpenAlex, Steven D. Nathan has authored 319 papers receiving a total of 14.3k indexed citations (citations by other indexed papers that have themselves been cited), including 267 papers in Pulmonary and Respiratory Medicine, 89 papers in Surgery and 60 papers in Physiology. Recurrent topics in Steven D. Nathan's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (218 papers), Pulmonary Hypertension Research and Treatments (128 papers) and Transplantation: Methods and Outcomes (83 papers). Steven D. Nathan is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (218 papers), Pulmonary Hypertension Research and Treatments (128 papers) and Transplantation: Methods and Outcomes (83 papers). Steven D. Nathan collaborates with scholars based in United States, Germany and United Kingdom. Steven D. Nathan's co-authors include Andrew F. Shorr, Oksana A. Shlobin, Scott D. Barnett, Shahzad Ahmad, Paul W. Noble, Lisa Lancaster, Marilyn K. Glassberg, David J. Lederer, Williamson Z. Bradford and Jeffrey J. Swigris and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and SHILAP Revista de lepidopterología.

In The Last Decade

Steven D. Nathan

295 papers receiving 14.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

2014 2.6k citations Talmadge E. King, Williamson Z. Bradford et al. profile →
International Guidelines for the Selection of Lung Transplant Candidates: 2006 Update—A Consensus Report From the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation

2006 737 citations Jonathan B. Orens, Steven D. Nathan et al. The Journal of Heart and Lung Transplantation profile →
Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis

2006 600 citations Steven D. Nathan, Scott D. Barnett et al. CHEST Journal profile →
Pulmonary hypertension in chronic lung disease and hypoxia

2018 428 citations Steven D. Nathan et al. European Respiratory Journal profile →
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

2021 336 citations Peter Smith, C. Q. Deng et al. profile →
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials

2015 320 citations Paul W. Noble, Carlo Albera et al. European Respiratory Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven D. Nathan United States	56	12.1k	3.5k	2.6k	1.4k	1.2k	319	14.3k
David J. Lederer United States	50	9.3k 0.8×	2.9k 0.8×	2.9k 1.1×	1.4k 1.0×	910 0.7×	225	13.0k
Steven A. Sahn United States	65	14.5k 1.2×	2.9k 0.8×	4.3k 1.7×	1.9k 1.3×	774 0.6×	242	17.8k
Demosthenes Bouros Greece	58	8.5k 0.7×	2.9k 0.8×	1.4k 0.5×	1.7k 1.2×	356 0.3×	377	11.9k
Marvin I. Schwarz United States	57	8.8k 0.7×	2.5k 0.7×	940 0.4×	1.4k 1.0×	337 0.3×	162	10.5k
Kevin R. Flaherty United States	55	9.1k 0.8×	3.0k 0.9×	760 0.3×	1.2k 0.8×	281 0.2×	196	10.9k
Borja G. Cosío Spain	57	5.5k 0.5×	3.3k 0.9×	2.4k 0.9×	1.0k 0.7×	320 0.3×	266	12.4k
Paul A. Corris United Kingdom	52	6.5k 0.5×	1.4k 0.4×	4.9k 1.8×	1.9k 1.3×	1.9k 1.5×	212	11.1k
Francesco De Cobelli Italy	50	3.1k 0.3×	1.6k 0.5×	2.3k 0.9×	1.5k 1.1×	2.0k 1.6×	357	10.5k
Toby M. Maher United Kingdom	63	12.7k 1.0×	3.8k 1.1×	794 0.3×	2.4k 1.7×	251 0.2×	437	15.6k
Roland M. du Bois United Kingdom	69	16.2k 1.3×	6.2k 1.8×	1.2k 0.4×	3.2k 2.3×	403 0.3×	143	19.5k

Countries citing papers authored by Steven D. Nathan

Since Specialization

Citations

This map shows the geographic impact of Steven D. Nathan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven D. Nathan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven D. Nathan more than expected).

Fields of papers citing papers by Steven D. Nathan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven D. Nathan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven D. Nathan. The network helps show where Steven D. Nathan may publish in the future.

Co-authorship network of co-authors of Steven D. Nathan

This figure shows the co-authorship network connecting the top 25 collaborators of Steven D. Nathan. A scholar is included among the top collaborators of Steven D. Nathan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven D. Nathan. Steven D. Nathan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nathan, Steven D., Ho Cheol Kim, Christopher S. King, et al.. (2025). Serial Pulmonary Hemodynamics in Patients with Idiopathic Pulmonary Fibrosis Listed for Lung Transplant. American Journal of Respiratory and Critical Care Medicine. 211(6). 984–991.

Nathan, Steven D., Jürgen Behr, Vincent Cottin, et al.. (2024). Study Design and Rationale for the TETON-PPF Phase 3, Randomized, Controlled Clinical Trial of Inhaled Treprostinil in the Treatment of Progressive Pulmonary Fibrosis. SHILAP Revista de lepidopterología. 3(2). 100124–100124. 3 indexed citations

Behr, Jürgen, Steven D. Nathan, Ulrich Costabel, et al.. (2023). Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies. Advances in Therapy. 40(9). 3937–3955. 6 indexed citations

King, Christopher S., Emily White, Shambhu Aryal, et al.. (2023). Factors associated with listing for lung transplantation in IPF patients: An analysis of the pulmonary fibrosis foundation registry. Heliyon. 9(8). e18618–e18618. 2 indexed citations

Cochrane, A., Deborah J. Levine, Mary Carmelle Philogene, et al.. (2022). Clinical features and allograft failure rates of pulmonary antibody-mediated rejection categories. The Journal of Heart and Lung Transplantation. 42(2). 226–235. 8 indexed citations

Chandel, Abhimanyu, Vikramjit Khangoora, Steven D. Nathan, et al.. (2021). Incidence and prognostic significance of pleural effusions in pulmonary arterial hypertension. Pulmonary Circulation. 11(2). 1–10. 5 indexed citations

Chandel, Abhimanyu, Alison Brown, A.C. Collins, et al.. (2020). High-Flow Nasal Cannula Therapy in COVID-19: Using the ROX Index to Predict Success. Respiratory Care. 66(6). 909–919. 113 indexed citations

Lancaster, Lisa, João A. de Andrade, Joseph D. Zibrak, et al.. (2017). Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. European Respiratory Review. 26(146). 170057–170057. 210 indexed citations

Esposito, Daina B., Stephan Lanes, Macarius Donneyong, et al.. (2015). Idiopathic Pulmonary Fibrosis in United States Automated Claims: Incidence, Prevalence, and Algorithm Validation. American Journal of Respiratory and Critical Care Medicine. 192(10). 1200–1207. 83 indexed citations

10.

King, Talmadge E., Carlo Albera, Williamson Z. Bradford, et al.. (2014). All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the Design and Execution of Clinical Trials. American Journal of Respiratory and Critical Care Medicine. 189(7). 825–831. 101 indexed citations

11.

Boyden, Jackelyn Y., et al.. (2014). Nebulized Medications for the Treatment of Dyspnea: A Literature Review. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 28(1). 1–19. 40 indexed citations

12.

King, Christopher S. & Steven D. Nathan. (2013). Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. Current Opinion in Pulmonary Medicine. 19(5). 466–473. 33 indexed citations

13.

Kottmann, R.M., Ajit A. Kulkarni, Elizabeth Lyda, et al.. (2012). Lactic Acid Is Elevated in Idiopathic Pulmonary Fibrosis and Induces Myofibroblast Differentiation via pH-Dependent Activation of Transforming Growth Factor-β. American Journal of Respiratory and Critical Care Medicine. 186(8). 740–751. 293 indexed citations

14.

Bois, Roland M. du, Steven D. Nathan, Luca Richeldi, Marvin I. Schwarz, & Paul W. Noble. (2012). Idiopathic Pulmonary Fibrosis: Lung Function Is a Clinically Meaningful Endpoint for Phase III Trials. American Journal of Respiratory and Critical Care Medicine. 186(8). 712–715. 64 indexed citations

15.

Montes‐Worboys, Ana, Nasreen Noor, Kamal A. Mohammed, et al.. (2011). Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis. European Respiratory Journal. 39(1). 133–140. 68 indexed citations

16.

Nathan, Steven D., Oksana A. Shlobin, Nargues Weir, et al.. (2011). Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium. CHEST Journal. 140(1). 221–229. 259 indexed citations

17.

Eberlein, Michael, Solbert Permutt, Robert H. Brown, et al.. (2010). Supranormal Expiratory Airflow after Bilateral Lung Transplantation Is Associated with Improved Survival. American Journal of Respiratory and Critical Care Medicine. 183(1). 79–87. 33 indexed citations

18.

Nathan, Steven D.. (2008). Pulmonary hypertension in interstitial lung disease: PH in interstitial lung disease. International Journal of Clinical Practice. 62. 21–28. 9 indexed citations

19.

Nathan, Steven D., Paul W. Noble, & Rubin M. Tuder. (2007). Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine. 175(9). 875–880. 157 indexed citations

20.

Nathan, Steven D., Scott D. Barnett, Donald L. Helman, et al.. (2004). Interferon gamma-1b as Therapy for Idiopathic Pulmonary Fibrosis. Respiration. 71(1). 77–82. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact